Swedish Orphan Biovitrum AB (MEX:SOBI N) 3-Year Share Buyback Ratio : -3.60% (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Swedish Orphan Biovitrum AB 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Swedish Orphan Biovitrum AB's current 3-Year Share Buyback Ratio was -3.60%.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's 3-Year Share Buyback Ratio or its related term are showing as below:

MEX:SOBI N' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -33.4 Med: -3.1 Max: -0.2
Current: -3.6

During the past 13 years, Swedish Orphan Biovitrum AB's highest 3-Year Share Buyback Ratio was -0.20%. The lowest was -33.40%. And the median was -3.10%.

MEX:SOBI N's 3-Year Share Buyback Ratio is ranked worse than
54.51% of 677 companies
in the Drug Manufacturers industry
Industry Median: -2.2 vs MEX:SOBI N: -3.60

Competitive Comparison of Swedish Orphan Biovitrum AB's 3-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Swedish Orphan Biovitrum AB 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Swedish Orphan Biovitrum AB (MEX:SOBI N) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Swedish Orphan Biovitrum AB 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (MEX:SOBI N) » Definitions » 3-Year Share Buyback Ratio

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden 1SOBI:Italy SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines